Registration:

Transcription

1 INTERNATIONAL SYMPOSIUM Genes, genomes and the new paradigm of Personalized Healthcare Speakers Centro de Convenciones Gran Sevilla. Hotel Barceló Renacimiento Seville, november, 19, 2009 Registration:

2 Jaume Bertranpetit Jaume Bertranpetit is Professor of Biology at the School of Health and Life Sciences, Pompeu Fabra University (Barcelona), and Director and Group leader of the Unitat de Biologia Evolutiva in this University, and promoter of the recently created Institute for Evolutionary Biology, IBE (UPF-CSIC). Previously, he was Professor at Barcelona University. His research field covers many aspects of the study of human genome variation and diversity: human population genetics, molecular evolution, comparative genomics and the interaction between human evolutionary biology and other fields, including medicine, genetics of complex diseases, statistical genetics and others. Recent publications are mainly focused on the footprint of natural selection in the human genome and the emerging field of Evolutionary Systems Biology. He has published over 270 research papers, most of them since genome studies became his major dedication in Professor Bertranpetit is a member of Institut d'estudis Catalans and a number of international organizations. Currently he is also director of the Spanish National Genotyping Center (CeGen), and ICREA, an independent agency to attract research talent to Catalonia. Jacky Vonderscher Jacky Vonderscher, PhD, obtained an engineering degree in biological chemistry from the National Institute of Applied Sciences (INSA-Lyon, France) in 1977 and Ph.D. in biochemistry from the University of Geneva in Between 1978 and 2008 he was employee of Novartis (formerly Sandoz), where he held various positions in Drug Development, such as Head of the Drug Metabolism and Pharmacokinetics department, Head of Drug Development for NIBR (Novartis Institute for Biomedical Research), Global Head of BioMarker Development and Head of Exploratory Development in Europe, among other functions. In he initiated the first 2 CRADA with the FDA in line with the Critical Path Initiative, one of them paving the way to the Predictive Safety Testing Consortium for which he served as the Industry co-director and co-chair of the Nephrotoxicity Working Group. This led to the first submission of 7 newly qualified biomarkers of Drug Induced Kidney Injury to the FDA and EMEA in a joint VXDS (Voluntary Exploratory Data Submission) which were recently approved by the FDA for regulatory decision making. In 2008, he joined Roche as Global Head of Molecular Medicine Labs (MML). In this new role his function is supporting all pharma and diagnostic project teams to foster Personalized Health Care. MML provide cutting edge technologies (genetics, genomic,

3 proteomics, molecular histo-pathology, ) and state of the art infrastructures (Roche Clinical Sample Repository, ) to discover, develop and implement biomarkers from early Discovery to Market use. Shomi Bhattacharya Shomi Bhattacharya is the Director of the Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER) and Associate Director of the Andalusian Program of Genetics. He is also Professor of Experimental Ophtalmology at University College London, and since 2006 holds an Excellence Professorship of the French Republic at Pierre et Marie Curie University in Paris. Dr. Bhattacharya is member elect of the British Academy of Medical Sciences since 2001, and an international advisor for several research institutions in human genetics as well as the National Eye Institute of the US National Institutes of Health. A chemist, he obtained his PhD in Clinical Biochemistry at Newcastle University, and worked as a researcher at the MRC Human Genetics Unit in Edinburgh. He was a founding member of the Centre for Human Genetics at University College London. Dr. Bhattacharya has presented dozens of seminars and courses and led research projects in different universities accross the world, has received numerous awards in his career, and is author of more than 280 articles in high impact scientific journals such as Nature, Cell, Nature Genetics, and American Journal of Genetics, which have received over 5,000 citations in research papers. José Baselga José Baselga received his MD degree from Universidad Autónoma de Barcelona in 1982, and completed Internal Medicine residencies at Vall d Hebron University Hospital (Barcelona) and the State University of New York. After a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center (New York, USA), he joined the staff at the Breast Medicine Service until he returned to Spain in Currently, he is Director of the Vall d Hebron Institute of Oncology (VHIO), Head of Medical Oncology and Director of the Division of Medical Oncology, Hematology and Radiation Oncology at Vall d Hebron Hospital, and a Professor of Medicine at Universidad Autónoma de Barcelona. Dr. Baselga is the Chairman of SOLTI, the Spanish Breast Cancer Cooperative Group. His main areas of research interest are breast cancer and translational and early clinical research in the field of growth factor receptors and downstream molecules as targets for breast cancer therapy. He has been involved in the clinical development of a number of new anti-cancer agents, and conducted the initial clinical trials with monoclonal antibodies cetuximab and trastuzumab.

4 Dr. Baselga is the author of more than 200 peer-reviewed articles, in addition to over 300 abstracts and book chapters. He sits in the editorial boards of Cancer Cell, Clinical Cancer Research, Journal of Clinical Oncology and Annals of Oncology. He is a member of the American Association of Cancer Research (AACR- Board of Directors, Scientific Council and several committees), and the Scientific Advisory Committee of the Ludwig Institute for Cancer Research, and has served as member of the Board of Directors of the European Organization of Research on Cancer Treatment (EORTC) and the American Society of Clinical Oncology (ASCO). Since 2008 he s the President of the European Society of Medical Oncology (ESMO). Alain Fischer Alain Fischer obtained his degree and PhD in Medicine at Paris University. He completed his postdoctoral training at University College London with Marc Feldmann and Peter Beverley. Currently, he is Professor of Pediatrics at University Paris- Descartes, Director of the Pediatric Immunology and Hematology Department, at Hospital Necker-Enfants malades (Paris), and head of the INSERM research laboratory 'Développement normal et pathologique du systeme immunitaire'. In addition he is director of the Imagine Institute (Institut de recherche sur les maladies génétiques) at Hospital Necker. He has authored more than 500 publications on genetic defects of the immune system and their treatment. He is a member of the European Molecular Biology Organisation (EMBO) and of the French National Academy of Sciences. Among other distinctions for his career, he is the recipient of the Louis Jeantet (2001) and Descartes (2005) prizes. Kathryn Phillips Kathryn A. Phillips PhD is Professor of Health Economics and Health Services Research and Director, Center for Translational and Policy Research on Personalized Medicine at the University of California, San Francisco (UCSF). She holds appointments in the Department of Clinical Pharmacy, the Institute for Health Policy Studies, and the Comprehensive Cancer Center. Dr. Phillips holds degrees from the University of California-Berkeley, Harvard, and the University of Texas at Austin and previously spent eight years working for the federal government in Texas and Washington, D.C. Dr. Phillips research focuses on how health care is organized, delivered, and financed in the US. She focuses on personalized medicine targeting health care interventions to patients based on their genetics and the impact of personalized medicine and targeted therapies on clinical care, health economics, and health policy. Her emphasis is in the area of cancer screening and treatment. Dr. Phillips conducts cross-disciplinary research across the basic, clinical, and social sciences and also across academia, industry, and government. She has served as an adviser to many government and

5 industry groups as well as for start-up companies and venture capital firms. Dr Phillips is the Founder and Director of the UCSF Center on Translational and Policy Research on Personalized Medicine, which is focusing on the translation of cancer therapies ($8Million in funding from the National Institutes of Health and several foundations). She has published ~ 100 peer-reviewed articles in policy and clinical journals, including widely read journals such as JAMA, New England Journal of Medicine, and Health Affairs and serves on the editorial board for four journals. Bruno Flamion Bruno Flamion, MD, PhD, is a Belgian national. He graduated from the Medical School of the University of Brussels and specialized in internal medicine and nephrology, then obtained a PhD in Physiological Sciences in 1992 and worked at the National Institutes of Health (USA) in Bethesda, MD, between 1988 and 1992 and for the Belgian National Fund for Scientific Research, He is now Full Professor in Physiology and Pharmacology at the University of Namur, Belgium where he heads the Laboratory of Physiology and Pharmacology. His main research interest is in hyaluronidases. (EMEA) in London, he has been a member of the CHMP, the Efficacy Working Party and the Therapeutic Group on Pharmaco kinetics, as well as vice-chairman of the Pharmaco genetics Working Party, since He was appointed chairman of the Scientific Advice Working Party in April 2005 and has become a member of the new Committee for Advanced Therapies (CAT) which started its activities in January Bruno Flamion is also a member of the Regulations Advisory Board of the Centre for Medicines Research (CMR), International Institute for Regulatory Science. His continued activities in basic research and teaching make Bruno Flamion a strong supporter of increased scientific interactions between pharma leaders, regulatory bodies and the academia. Since 1999 Bruno Flamion has been a medical and pharmacological expert for what has become the Belgian Federal Agency for Medicinal and Health Products (FAMHP). At the European Medicines Agency

6 Scretaría Técnica Atril Congresos: Tel.: / Fax: secretaria@atrilcongresos.com Organized by: In Collaboration with: